BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Samanta K, Setua S, Kumari S, Jaggi M, Yallapu MM, Chauhan SC. Gemcitabine Combination Nano Therapies for Pancreatic Cancer. Pharmaceutics. 2019;11. [PMID: 31689930 DOI: 10.3390/pharmaceutics11110574] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Tarannum M, Vivero-Escoto JL. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. Adv Drug Deliv Rev 2022;187:114357. [PMID: 35605679 DOI: 10.1016/j.addr.2022.114357] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Sharma M, Bakshi AK, Mittapelly N, Gautam S, Marwaha D, Rai N, Singh N, Tiwari P, Aggarwal N, Kumar A, Mishra PR. Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer. Journal of Controlled Release 2022. [DOI: 10.1016/j.jconrel.2022.04.007] [Reference Citation Analysis]
3 Kashyap VK, Peasah-darkwah G, Dhasmana A, Jaggi M, Yallapu MM, Chauhan SC. Withania somnifera: Progress towards a Pharmaceutical Agent for Immunomodulation and Cancer Therapeutics. Pharmaceutics 2022;14:611. [DOI: 10.3390/pharmaceutics14030611] [Reference Citation Analysis]
4 Bibi S, Ur-rehman S, Khalid L, Bhatti IA, Bhatti HN, Iqbal J, Bai FQ, Zhang H. Investigation of the adsorption properties of gemcitabine anticancer drug with metal-doped boron nitride fullerenes as a drug-delivery carrier: a DFT study. RSC Adv 2022;12:2873-87. [DOI: 10.1039/d1ra09319c] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Singh B, Maharjan S, Pan DC, Zhao Z, Gao Y, Zhang YS, Mitragotri S. Imiquimod-gemcitabine nanoparticles harness immune cells to suppress breast cancer. Biomaterials 2022;280:121302. [PMID: 34894584 DOI: 10.1016/j.biomaterials.2021.121302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Tang S, Hang Y, Ding L, Tang W, Yu A, Zhang C, Sil D, Xie Y, Oupický D. Intraperitoneal siRNA Nanoparticles for Augmentation of Gemcitabine Efficacy in the Treatment of Pancreatic Cancer. Mol Pharm 2021;18:4448-58. [PMID: 34699242 DOI: 10.1021/acs.molpharmaceut.1c00653] [Reference Citation Analysis]
7 Demirtürk N, Bilensoy E. Nanocarriers targeting the diseases of the pancreas. Eur J Pharm Biopharm 2021:S0939-6411(21)00337-4. [PMID: 34852262 DOI: 10.1016/j.ejpb.2021.11.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
8 Aghamiri S, Raee P, Talaei S, Mohammadi-Yeganeh S, Bayat S, Rezaee D, Ghavidel AA, Teymouri A, Roshanzamiri S, Farhadi S, Ghanbarian H. Nonviral siRNA delivery systems for pancreatic cancer therapy. Biotechnol Bioeng 2021. [PMID: 34170520 DOI: 10.1002/bit.27869] [Reference Citation Analysis]
9 Li Y, Hou H, Zhang P, Zhang Z. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy. Drug Deliv 2020;27:1044-53. [PMID: 32633576 DOI: 10.1080/10717544.2020.1785049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
10 Hua YQ, Zhang K, Sheng J, Ning ZY, Li Y, Shi WD, Liu LM. NUCB1 Suppresses Growth and Shows Additive Effects With Gemcitabine in Pancreatic Ductal Adenocarcinoma via the Unfolded Protein Response. Front Cell Dev Biol 2021;9:641836. [PMID: 33855021 DOI: 10.3389/fcell.2021.641836] [Reference Citation Analysis]
11 Habib S, Singh M. Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine-Combination Therapy. Nanomaterials (Basel) 2021;11:597. [PMID: 33673636 DOI: 10.3390/nano11030597] [Reference Citation Analysis]
12 Jindal A, Sarkar S, Alam A. Nanomaterials-Mediated Immunomodulation for Cancer Therapeutics. Front Chem 2021;9:629635. [PMID: 33708759 DOI: 10.3389/fchem.2021.629635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Maniam G, Mai CW, Zulkefeli M, Fu JY. Co-encapsulation of gemcitabine and tocotrienols in nanovesicles enhanced efficacy in pancreatic cancer. Nanomedicine (Lond) 2021;16:373-89. [PMID: 33543651 DOI: 10.2217/nnm-2020-0374] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
14 Liu Y, Shi C, He Z, Zhu F, Wang M, He R, Zhao C, Shi X, Zhou M, Pan S, Gao Y, Li X, Qin R. Inhibition of PI3K/AKT signaling via ROS regulation is involved in Rhein-induced apoptosis and enhancement of oxaliplatin sensitivity in pancreatic cancer cells. Int J Biol Sci 2021;17:589-602. [PMID: 33613115 DOI: 10.7150/ijbs.49514] [Reference Citation Analysis]
15 Vu MT, Le NTT, Pham TL, Nguyen NH, Nguyen DH, Agrawal G. Development and Characterization of Soy Lecithin Liposome as Potential Drug Carrier Systems for Codelivery of Letrozole and Paclitaxel. Journal of Nanomaterials 2020;2020:1-9. [DOI: 10.1155/2020/8896455] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
16 Yin N, Yu H, Zhang X, Lv X. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib. Drug Des Devel Ther 2020;14:4465-75. [PMID: 33122890 DOI: 10.2147/DDDT.S270303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Ferreira NN, Boni FI, Baltazar F, Gremião MP. Validation of an innovative analytical method for simultaneous quantification of alpha-cyano-4-hydroxycinnamic acid and the monoclonal antibody cetuximab using HPLC from PLGA-based nanoparticles. Journal of Pharmaceutical and Biomedical Analysis 2020;190:113540. [DOI: 10.1016/j.jpba.2020.113540] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
18 Thomas A, Samykutty A, Gomez-Gutierrez JG, Yin W, Egger ME, McNally M, Chuong P, MacCuaig WM, Albeituni S, Zeiderman M, Li M, Edil BH, Grizzle WE, McMasters KM, McNally LR. Actively Targeted Nanodelivery of Echinomycin Induces Autophagy-Mediated Death in Chemoresistant Pancreatic Cancer In Vivo. Cancers (Basel) 2020;12:E2279. [PMID: 32823919 DOI: 10.3390/cancers12082279] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Ashrafizadeh M, Ang HL, Moghadam ER, Mohammadi S, Zarrin V, Hushmandi K, Samarghandian S, Zarrabi A, Najafi M, Mohammadinejad R, Kumar AP. MicroRNAs and Their Influence on the ZEB Family: Mechanistic Aspects and Therapeutic Applications in Cancer Therapy. Biomolecules 2020;10:E1040. [PMID: 32664703 DOI: 10.3390/biom10071040] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
20 Zhou J, Qie S, Fang H, Xi J. MiR-487a-3p suppresses the malignant development of pancreatic cancer by targeting SMAD7. Exp Mol Pathol 2020;116:104489. [PMID: 32622014 DOI: 10.1016/j.yexmp.2020.104489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Li M, van Raath MI, Khakpour S, Seçilir A, Sliggers BC, Huang X, Ding B, Storm G, van der Hulst RR, de Kroon AIPM, Heger M. In Vivo Assessment of Thermosensitive Liposomes for the Treatment of Port Wine Stains by Antifibrinolytic Site-Specific Pharmaco-Laser Therapy. Pharmaceutics 2020;12:E591. [PMID: 32630457 DOI: 10.3390/pharmaceutics12060591] [Reference Citation Analysis]
22 Hanurry EY, Mekonnen TW, Andrgie AT, Darge HF, Birhan YS, Hsu WH, Chou HY, Cheng CC, Lai JY, Tsai HC. Biotin-Decorated PAMAM G4.5 Dendrimer Nanoparticles to Enhance the Delivery, Anti-Proliferative, and Apoptotic Effects of Chemotherapeutic Drug in Cancer Cells. Pharmaceutics 2020;12:E443. [PMID: 32403321 DOI: 10.3390/pharmaceutics12050443] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
23 Madamsetty VS, Pal K, Dutta SK, Wang E, Mukhopadhyay D. Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer. Cancers (Basel) 2020;12:E1189. [PMID: 32397114 DOI: 10.3390/cancers12051189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Li T, Yan G, Bai Y, Wu M, Fang G, Zhang M, Xie Y, Borjigidai A, Fu B. Papain bioinspired gold nanoparticles augmented the anticancer potency of 5-FU against lung cancer. Journal of Experimental Nanoscience 2020;15:109-28. [DOI: 10.1080/17458080.2020.1746767] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
25 Wang Y, Jiang XY, Yu XY. BRD9 controls the oxytocin signaling pathway in gastric cancer via CANA2D4, CALML6, GNAO1, and KCNJ5. Transl Cancer Res 2020;9:3354-66. [PMID: 35117701 DOI: 10.21037/tcr.2020.03.67] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Wang J, He ZW, Jiang JX. Nanomaterials: Applications in the diagnosis and treatment of pancreatic cancer. World J Gastrointest Pharmacol Ther 2020; 11(1): 1-7 [PMID: 32405438 DOI: 10.4292/wjgpt.v11.i1.1] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
27 Chauhan SS, Shetty AB, Hatami E, Chowdhury P, Yallapu MM. Pectin-Tannic Acid Nano-Complexes Promote the Delivery and Bioactivity of Drugs in Pancreatic Cancer Cells. Pharmaceutics 2020;12:E285. [PMID: 32235765 DOI: 10.3390/pharmaceutics12030285] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]